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AbstrACt
Objective Expressing therapy benefit from a lifetime 
perspective, instead of only a 10-year perspective, is 
both more intuitive and of growing importance in doctor–
patient communication. In cardiovascular disease (CVD) 
prevention, lifetime estimates are increasingly accessible 
via online decision tools. However, it is unclear what gain 
in life expectancy is considered meaningful by those who 
would use the estimates in clinical practice. We therefore 
quantified lifetime and 10-year benefit thresholds at 
which physicians and patients perceive statin and 
antihypertensive therapy as meaningful, and compared the 
thresholds with clinically attainable benefit.
Design Cross-sectional study.
settings (1) continuing medical education conference 
in December 2016 for primary care physicians;(2) 
information session in April 2017 for patients.
Participants 400 primary care physicians and 523 
patients in the Netherlands.
Outcome Months gain of CVD-free life expectancy at 
which lifelong statin therapy is perceived as meaningful, 
and months gain at which 10 years of statin and 
antihypertensive therapy is perceived as meaningful. 
Physicians were framed as users for lifelong and 
prescribers for 10-year therapy.
results Meaningful benefit was reported as median (IQR). 
Meaningful lifetime statin benefit was 24 months (IQR 23–
36) in physicians (as users) and 42 months (IQR 12–42) in 
patients willing to consider therapy. Meaningful 10-year 
statin benefit was 12 months (IQR 10–12) for prescribing 
(physicians) and 14 months (IQR 10–14) for using 
(patients). Meaningful 10-year antihypertensive benefit 
was 12 months (IQR 8–12) for prescribing (physicians) 
and 14 months (IQR 10–14) for using (patients). Women 
desired greater benefit than men. Age, CVD status and co-
medication had minimal effects on outcomes.
Conclusion Both physicians and patients report a large 
variation in meaningful longevity benefit. Desired benefit 
differs between physicians and patients and exceeds what 
is clinically attainable. Clinicians should recognise these 
discrepancies when prescribing therapy and implement 
individualised medicine and shared decision-making. 
Decision tools could provide information on realistic 
therapy benefit.
IntrODuCtIOn  
Risk assessment is integral to the preven-
tion of cardiovascular disease (CVD). 
Accordingly, there is an increasing number 
of risk scores available to aid in the identi-
fication of individuals with a high CVD risk 
(eg, Framingham, Systemic Coronary Risk 
Evaluation [SCORE], QRISK).1 2 Some 
scores estimate individualised prognosis 
not only in terms of absolute risk but also 
in terms of life expectancy free of CVD. 
The use of these lifetime estimations has 
been endorsed by prevention guidelines to 
facilitate doctor–patient communication or 
cultivate patient motivation.3 4 
strengths and Limitations of the study:
 ► We examined benefit thresholds of specific real-life 
(non-idealised) agents, thus incorporating precon-
ceived notions about the costs, side effects and in-
conveniences of medication which are a daily part 
of clinical practice.
 ► In contrast to previous studies, we surveyed a large 
sample of both physicians and actual patients in 
comparable settings.
 ► The use of a multiple-choice voting system may 
have limited response variation.
 ► Further research would be necessary to analyse 
how these perspectives would relate to actual use 
of medication by patients and prescription of medi-
cation by physicians.
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In addition to prognosis, some algorithms also esti-
mate individual therapy benefit from common thera-
pies such as lipid-lowering and blood-pressure-lowering 
medications. However, measures such as absolute risk 
reduction or number needed to treat are often diffi-
cult for patients to understand.5 In contrast, gain in 
life expectancy may facilitate patient understanding of 
preventive therapy.6 7 Tools to estimate lifetime therapy 
benefit are increasingly accessible to both physicians 
and patients via online calculators. One such deci-
sion aid, the Joint British Societies for prevention of 
cardiovascular disease (JBS3) risk calculator,8 has 
been endorsed by international guidelines.3 These 
decision aids may facilitate shared decision-making 
and doctor–patient communication, both of growing 
importance in clinical practice and policy,9 even though 
evidence suggests that physicians may be insensitive to 
patient preferences when recommending therapy.10
Despite the guideline endorsed importance of lifetime 
estimates and an increased emphasis on doctor–patient 
communication and shared decision-making, little research 
has investigated what lifetime therapy benefit is deemed 
by both patients and prescribers as sufficient to offset the 
inconveniences of specific CVD pharmacotherapies. The 
framing (eg, positive or negative) and format (eg, absolute 
risk reduction or gain in life expectancy) of communica-
tion metrics influence both patient and physician opinions 
on therapy.11 As both lifetime estimates and decision tools 
gain accessibility in clinical practice, it becomes more essen-
tial to examine the perceptions of meaningful therapy and 
the potential discrepancies between physician and patient 
perceptions. Previous studies either did not survey both 
patients and physicians in similar settings, or were focused 
on situations which do not exist in clinical practice, such 
as hypothetical risk scenarios12 13 or  idealised medica-
tions.10 14–17 We therefore aimed to quantify perceptions 
on meaningful lifetime and 10-year benefit, defined as the 
gain in CVD-free life expectancy above which physicians 
(as users and prescribers) and patients consider statin and 
antihypertensive medication meaningful. We also aimed 
to compare these thresholds with what benefit is clinically 
achievable in the primary prevention setting.
MethODs
setting and participants
Two separate settings, in which a large number of patients 
and physicians could be recruited and surveyed, were 
chosen. Primary care physicians were recruited and surveyed 
on the same day among attendees of a national continuing 
medical education conference (Boerhaave ‘Progress and 
Practice’), in Leiden, The Netherlands (8 December 
2016) which was targeted to primary prevention healthcare 
providers. Only survey participants reporting themselves 
as primary care physicians were included in the analyses. 
Patients were recruited and surveyed during three separate 
plenary sessions at a 1-day information conference targeted 
to primary and secondary CVD prevention patients at the 
University Medical Center Utrecht in the Netherlands 
(8 April 2017). All surveyed patients were included in the 
analyses.
survey preparation and administration
A pretest session involving fifty primary care physicians 
was conducted in November 2016 to review the research 
questions and proposed survey, and to guide the multi-
ple-choice answer options of the electronic (physician) 
or paper (patient) questionnaires ultimately used for data 
collection (online supplementary A and B). The finalised 
surveys were subsequently administered at the respective 
sessions (Boerhaave and Utrecht). To ensure informed and 
comparable responses, an audience-appropriate 10 minute 
introduction on individual therapy-benefit was given prior 
to each session (online supplementary C). In this introduc-
tion, examples of lifetime benefit from smoking cessation 
and aspirin therapy were provided.1 18 The structure of the 
introduction and survey was the same in both physician and 
patient questionnaires. The survey questions were presented 
centrally and sequentially by the researcher, thus preventing 
participants from viewing either previous or future ques-
tions or benefitting from time-saving heuristics. The ques-
tions were verbally explained before participants were given 
the opportunity to respond. At the start of each session, all 
participants were informed that a voluntary survey would be 
conducted and data would be collected and treated anon-
ymously. The study was conducted in accordance with the 
principles of the Declaration of Helsinki and prospectively 
granted exempt status by the Medical Ethics Committee of 
the University Medical Center Utrecht.
Outcome definition
Lifetime benefit thresholds for physicians and patients 
were quantified as the gain in CVD-free life expectancy 
desired prior to considering or continuing personal 
statin therapy (ie, the benefit considered meaningful). 
Ten-year benefit thresholds were quantified as the gain 
in CVD-free life expectancy desired for 10 years of 
both statin and antihypertensive medication use prior 
to considering or continuing a prescription (physi-
cians) or personal use (patients). Physicians were thus 
framed as users for lifetime thresholds and prescribers 
for 10-year thresholds. For an exploratory analysis, the 
outcome was framed differently and participants were 
asked to report the number of years they would be 
willing to take statin medication provided the therapy 
would give a 1-year gain in CVD-free expectancy.
Guideline recommendations and participant views of 
meaningful therapy
European Society of Cardiology (ESC) guideline recom-
mendations on lipid19 and blood pressure therapy20 
were compared with what participants viewed as mean-
ingful therapy. The ESC-SCORE algorithm for low-risk 
countries was used to establish which risk factor combi-
nations had sufficient 10-year risk of CVD mortality 
to be eligible for lipid-lowering therapy.19–21 In order 
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to establish which risk factor combinations would 
be treated based on participant views of meaningful 
therapy, clinically attainable benefit from statin 
and antihypertensive medication was estimated and 
compared with views of meaningful benefit. The JBS 
risk calculator22 was used to estimate clinically attainable 
benefit in terms of gain in CVD-free life expectancy for 
each of the 600 risk factor combinations (age, systolic 
blood pressure (SBP), smoking status, sex, and total 
cholesterol) of a national ESC-SCORE chart variant.3 23 
Clinically attainable gain from statin medication was 
estimated with simvastatin 40 mg, a mid-potency statin 
commonly prescribed as initial therapy24 which reduces 
LDL-C (low-density lipoprotein cholesterol) levels by 
37% irrespective of baseline level.25 Clinically attain-
able gain from blood-pressure lowering therapy awas 
estimated with a single, initial antihypertensive medi-
cation, using the formula 9.1 mm Hg +0.10 mm Hg* 
(current SBP - 154 mm Hg).26 To express the clinically 
attainable benefit per year of medication use, the gain 
in CVD-free life expectancy estimated by the calcu-
lator (ie, the lifetime benefit) was divided by the total 
remaining on-therapy CVD-free life-years estimated 
by the calculator (ie, the duration of medication use 
required to achieve this lifetime benefit). The esti-
mated clinically attainable gain per 10 years of medica-
tion use was graphically juxtaposed against participant 
views of meaningful benefit, expressed as months gain 
in CVD-free life expectancy desired for 10 years of use 
prior to considering or continuing prescription (physi-
cians) or personal use (patients). For clarity, all values 
used for the calculations and a calculation example are 
provided in the online supplementary D and E.27–29
Data analysis
Age was converted to numeric values. Thresholds in terms 
of minimal desired months gain were reported as median 
(IQR) within each group. Wilcoxon rank-sum test and 
Spearman correlations were used to analyse lifetime 
thresholds according to certain characteristics predefined 
to be potentially of influence on response: age, sex, use of 
either statin or antihypertensive medication (yes/no) and 
presence of CVD (yes/no).30 31 Paired samples Wilcoxon 
signed-rank tests were used to assess response differences 
between 10-year statin and antihypertensive medication 
thresholds. Missing values were not imputed, and the 
number of participants in each analysis reported. Anal-
yses were performed using R-Statistical Software, V.3.1.1.
Patient and public involvement
The study had been designed to survey the opinion of 
a large group of both patients and physicians to better 
understand their priorities and preferences. Both patient 
organisations and primary care physicians were involved 
during study preparation. The research question and 
study design evolved from a discussion session with a 
patient panel at PGOSupport conference, an indepen-
dent nation-wide network for patient organisations, held 
in Amstelveen, the Netherlands in April 2016. Physicians 
were involved in the pretest sessions in Roermond, the 
Netherlands in November 2016. Participants were not 
involved in finding the optimal study recruitment proce-
dures. The findings from this study will be disseminated to 
physicians and patients via conferences and newsletters.
resuLts
Participants and response
Of the 455 physician survey respondents, the 400 partic-
ipants reporting themselves as primary care physicians 
were included in the analyses. The participant charac-
teristics of the included 400 primary care physicians and 
523 patients are depicted in table 1. Physician sex and 
age distribution reflected the national primary care physi-
cian population: 54% men and 46% women. Median age 
was 55 years (IQR 40–60) in physicians and 69 years (IQR 
Table 1 Baseline characteristics
Primary care 
physicians Patients
n=400 n=523
Gender
  Male 195 (54%)* 263 (50%)
  Female 164 (46%) 260 (50%)
Age, years
  ≤34 31 (8%)* 12 (2%)
  35–45 67 (18%) 15 (3%)
  46–52 63 (17%) 19 (4%)
  53–57 67 (18%) 21 (4%)
  58–62 89 (24%) 57 (11%)
  63–67 41 (11%) 110 (21%)
  68–72 6 (2%) 130 (25%)
  ≥73 3 (1%) 159 (30%)
Statin use
  Yes – 298 (57%)†
  No – 166 (32%)
  Previously used – 55 (11%)
  Unknown – 4 (1%)
Antihypertensive use
  Yes – 301 (58%)† 
  No – 187 (36%)
  Previously used – 30 (6%)
  Unknown – 4 (1%)
Clinically manifest CVD
  Yes – 283 (54%)† 
  No – 238 (46%)
Missing data for baseline characteristics: * between 8% and 10%; 
†< 1%. Clinically manifest cardiovascular disease (CVD) is defined 
as presence of one or more of the following: coronary heart 
disease, cerebrovascular disease and peripheral artery disease.
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63–74) in patients. Approximately half (54%, n=283) of 
patients reported clinical manifestations of CVD, defined 
as coronary heart disease (n=131, 25.0%), cerebrovas-
cular disease (n=63, 12.0%), peripheral artery disease 
(n=24, 4.6%) or multiple CVD manifestations (n=65, 
12.5%).
Personal meaningful lifetime benefit
Meaningful lifetime benefit is presented in figure 1. In total, 
12.9% (n=51) of physicians considered the maximum gain 
(42 months) insufficient for personal use. The remaining 
physicians desired 24 months (IQR 23–36) gain. Age was 
not associated with physician thresholds (Spearman’s 
rho −0.07, p=0.20). Physician responses differed by sex 
(rank-sum test, p=0.003): men, 24 months (IQR 12–36); 
women 30 months (IQR 24–36). In comparison, 20.0% 
(n=100) of patients considered the maximum gain (also 
42 months) insufficient. The remaining patients desired 
42 months (IQR 12–42) gain. Older patients desired 
marginally higher gain than younger patients (per year, 
Spearman’ s rho 0.10, p=0.04). Patient responses differed 
by sex (rank-sum test, p=0.04): men, 36 months (IQR 
6–42); women 42 months (IQR 24–42) (online supple-
mentary figures 1 and 2). Median threshold did not differ 
between patients on and off-therapy (rank-sum test, 
p=0.47), although more patients off-therapy (42.1%) than 
on-therapy (8.1%) considered the maximum gain of 42 
months insufficient. Similarly, median threshold did not 
differ between patients with and without clinically mani-
fest CVD (rank-sum test, p=0.49), although more patients 
without CVD (24.5%) than with CVD (16.3%) consid-
ered the maximum gain insufficient (online supple-
mentary figures 3 and 4). Similar results were obtained 
in the exploratory analysis when participants were asked 
to report the number of years they would be willing to 
take a statin for 1-year gain of CVD-free life expectancy. 
In total, 14.2% of physicians and 21.5% of patients were 
not willing to use a statin provided the thresholds. For 
those willing to use therapy, the time trade-off was similar 
to the main analysis: median physicians 10 years (IQR 
10–20) and median patients 10 years (IQR 5–20). Results 
are depicted in the online supplementary figure 5.
Meaningful 10-year statin and antihypertensive thresholds
Meaningful 10-year thresholds for statins are depicted in 
figure 2A. In total, 4.4% (n=17) of physicians considered 
the maximum gain (14 months for every 10 years of use) 
insufficient to prescribe statins. The median meaningful 
gain for every 10 years of use was 12 months (IQR 10–12) 
for the remaining physicians. In comparison, 16.1% 
(n=80) of patients considered the maximum gain insuf-
ficient and the median 10-year threshold was 14 months 
(IQR 10–14). Meaningful 10-year thresholds for antihy-
pertensive medication are depicted in figure 2B. Physi-
cian responses for statin and antihypertensive medication 
differed (paired signed-rank test, Z=3736, p<0.001). In 
total, 2.3% (n=9) of physicians considered the maximum 
gain (14 months for every 10 years of use) insufficient 
to prescribe antihypertensive therapy, and the median 
meaningful gain for every 10 years of use was 12 months 
(IQR 8–12). Patient responses did not differ for statin 
and antihypertensive medications (Z=1795, p=0.36).
Guideline recommendations and participant views of 
meaningful therapy
ESC guideline recommendations and participant views 
of meaningful therapy for statin medications are juxta-
posed against clinically attainable lifetime benefit in 
figure 3. Colours depict (non)-concordance between 
guideline recommended therapy and participant views 
of meaningful benefit. The clinically attainable gain in 
CVD-fee life expectancy from lifelong use of simvastatin 
40 mg ranged from 4 to 49 months. Larger gains were 
seen in younger individuals with high SBP and lipid levels 
Figure 1 Months gain in CVD-free life expectancy above which physicians (as users) and patients perceive lifelong statin 
therapy as meaningful. Missing responses was seen in 5 physicians (1.3%) and 23 patients (4.4%). CVD, cardiovascular 
disease.
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and smaller gains were seen in older individuals with 
low risk factor levels. Guideline recomended treatment 
is concordant with participant views if the clinically 
attainable gain in CVD-free life expectancy per 10 years 
of medication is equal to or greater than the reported 
meaningful benefit thresholds for prescribing and using 
Figure 2 Months gain in CVD-free life expectancy above which physicians (as prescribers) and patients (as users) consider (A) 
statin and (B) antihypertensive therapy meaningful. Missing responses was seen in 9 physicians (2.3%) and 27 patients (5.2%) 
for statin medication and 8 physicians (2.0%) and 28 patients (5.4%) for antihypertensive medication. CVD, cardiovascular 
disease.
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Figure 3 Numbers represent total gain (in months) of CVD-free life expectancy to be attained from lifelong therapy with 
simvastatin 40 mg for the specific combination of age, sex, lipid-profile, blood pressure and smoking status calculated with the 
JBS3 risk score. Colours represent the (non)-concordance between ESC guideline recommendations and participant views of 
meaningful therapy. CVD, cardiovascular disease; ESC, European Society of Cardiology.
Figure 4 Numbers represent total gain (in months) of CVD-free life expectancy to be attained from lifelong therapy with a 
single blood-pressure-lowering medication for the specific combination of age, sex, lipid profile, blood pressure and smoking 
status calculated with the JBS3 risk score. Colours represent the (non)-concordance between ESC guideline recommendations 
and participant views of meaningful therapy. CVD, cardiovascular disease; ESC, European Society of Cardiology. 
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(ie, physician median 12 months for every 10 years of use 
and patient median 14 months for every 10 years of use). 
Figure 4 provides the same information for a single, daily, 
antihypertensive medication; clinically attainable life-
time gain in CVD-fee life expectancy ranged from 4 to 
35 months and followed a similar distribution pattern to 
statin therapy.
DIsCussIOn
Meaningful statin and antihypertensive therapy for life-
time and 10 years of use was quantified in 400 primary 
care physicians and 523 patients. A high degree of vari-
ation in what was perceived as meaningful therapy was 
reported within both patients and physicians. Patients 
consistently desired a higher lifetime benefit for medica-
tion use than physicians. Women desired a higher benefit 
from a statin than men in both participant groups. Physi-
cians desired a slightly higher benefit from a statin than 
from an antihypertensive medication. Age had minimal 
influence on thresholds in patients. Compared with those 
with CVD, a greater percentage of healthy respondents 
were not willing to consider statin therapy. However, the 
median thresholds for respondents who were willing to 
consider therapy did not differ between these two patient 
groups. Similar results were found when patients on-pre-
ventative and off-preventative therapy were compared. 
The majority of respondents desired a gain in CVD-free 
life expectancy above what is generally achievable with 
lifelong use of a single tablet in the primary prevention 
setting.
To our knowledge, this is the first study examining medi-
cation-specific thresholds in both physicians and patients 
in terms of gain in life expectancy. The considerably high 
thresholds found in our study can be explained by the 
use of specific medications and not an idealised tablet. 
Previous studies have either focused on non-lifetime 
metrics in hypothetical risk scenarios12 13or on idealised 
medications with negligible costs, side effects or follow-up 
requirements.10 14–17 Even in these idealised situations, 
the benefit desired by patients is large and often greater 
than the benefit desired by physicians.12 13 30 For an ideal-
ised pill, the general public desires a 6-month gain in 
life expectancy.16 Healthcare employees are willing to 
sacrifice 12.3 weeks of life to avoid taking a pill.32 Such 
isolated disutility of pill-taking is applicable in cost-effec-
tiveness studies. However, it does not assess the real-life 
perceived costs, side effects and other inconveniences of 
specific medications which are encountered in clinical 
practice.
In this study, patients without CVD or current preven-
tive therapy were more often unwilling to consider 
therapy. However, for those patients who were willing 
to consider statin therapy, no group differences were 
found in median CVD-free life expectancy desired. The 
similar numeric thresholds align with exiting literature in 
which socioeconomic factors effected willingness to use 
medication, whereas traditional risk factors such as the 
presence of CVD and use of antihypertensive or statin 
therapy did not.33 Patients view hypertension treatment 
as more necessary and effective than hyperlipidaemia 
treatment.34 However, patients in our study did not distin-
guish between statin and antihypertensive medications, 
indicating that this discrepancy does not apply if therapy 
imparts identical benefit. Physicians however did desire 
greater benefit from statins than antihypertensive medi-
cations. Statin side effects, but not necessarily antihyper-
tensive side effects, have received wide-spread attention 
over the previous decades. Negative portrayal of statins in 
the media and academic press influences healthcare-re-
lated behaviour and coincides with a decrease in statin 
use.35 Myalgia frequency is approximately twice as high 
in patients on statins as on placebo in clinical trials.36 
However, the frequency is considerably higher in observa-
tional studies,37 and clinicians are confronted with obser-
vational frequencies in clinical practice.
Compared with a risk-based treatment strategy in preven-
tion guidelines, treatment based on meaningful therapy 
thresholds would treat fewer risk factor combinations 
and would produce a shift in eligibility. This shift would 
exclude mostly older individuals with a high 10-year risk 
and include younger individuals with a low 10-year risk but 
a high risk factor burden (i.e. high lipid levels and high 
SBP), for whom treatment is not indicated according to 
risk-based guidelines. A previous study investigating eligi-
bility based on an individualised benefit-based approach 
described an eligibility shift similar to the one seen in the 
present study. An earlier study based eligibility cut-offs on 
a 10-year absolute risk reduction of ≥2.3%.38 However, 
this cut-off was not based on patient perceptions, but on 
the minimum statin benefit seen in primary prevention 
guidelines and resulted in a greater number of eligible 
patients (34%) compared with current practice (21%). 
Other studies have demonstrated that young individuals 
with a high risk factor burden have the greatest net-posi-
tive lifetime benefit from CVD prevention strategies, such 
as aspirin use1 and renin–angiotensin system inhibition.39 
As older patients had a minimal but significantly higher 
benefit threshold than younger patients, such a shift is 
congruent with user views. This shift is also congruent 
with changing insights into the benefits of deprescription 
of the elderly population.40
Lifetime-based decision tools have become more acces-
sible in clinical practice to both patients and physicians. 
It is therefore essential to address the high degree of 
variation in what is considered meaningful therapy in 
clinical practice. The discrepancy between perceived 
meaningful benefit and clinically attainable benefit 
should be addressed, and a patient’s satisfaction with 
the expected benefit of agreed upon therapy could be 
viewed as an additional quality of care indicator. However, 
guidelines need not adapt eligibility thresholds or target 
values based on perceptions of meaningful therapy. The 
number of prevented CVD events is ultimately deter-
mined by physicians and patients making guideline-based 
decisions. Misperceptions about perceived CVD risk are 
 o
n
 7 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021309 on 26 May 2018. Downloaded from 
8 Jaspers NEM, et al. BMJ Open 2018;8:e021309. doi:10.1136/bmjopen-2017-021309
Open Access 
commonplace,41 and it is conceivable that both physicians 
and patients overestimate realistic therapy benefit and 
may require guidance as to what longevity benefit can 
be realistically achieved. Such guidance could be easily 
incorporated into the same online decision aids which 
are currently available.
Certain strengths of this study should be highlighted. 
First, both parties of the shared decision-making process 
were informed and surveyed in comparable settings. Physi-
cians were representative of the general practitioner popu-
lation and both primary and secondary prevention patients 
were surveyed. As there was no evidence of difference in 
medians between patients with and without CVD, no strat-
ification based on primary or secondary prevention was 
necessary. Second, the number of incomplete responses 
was low for both physicians (1.3%–2.3%) and patients 
(4.4%–5.4%), indicating that both groups were suffi-
ciently informed to provide valid and reliable responses. 
Lastly, we examined benefit thresholds of specific real-life 
(non-idealised) agents, thus incorporating preconceived 
notions about the costs, side effects and inconveniences 
of medication which are a daily part of clinical practice. 
Certain study limitations must also be acknowledged. 
First, we were restricted to a multiple-choice voting system, 
which may have limited response variation. However, 
the observed variation in our study remained large and 
multiple-choice options were based on responses from a 
pretest session. Second, benefit–threshold associated with 
a single medication was surveyed. In practice, if LDL-C or 
SBP targets are not achieved, additional medication can 
be prescribed without necessarily increasing the number 
of tablets used daily. However, the magnitude of the 
opinion-based benefit–thresholds are not altered by this 
limitation. Third, patients were recruited at a large, infor-
mation conference on CVD prevention and may repre-
sent a population more interested in CVD prevention 
than average. Fourth, the survey was pretested in physi-
cians and subsequently adapted for patients. However, 
the survey and the preceding introduction were designed 
to maximise understandability and comparability. Fifth, 
clinically attainable benefit was estimated using the JBS3 
risk score and best available evidence from meta-analyses. 
However, the estimated benefit differs in populations 
with different event rates, such as people with clinically 
manifest CVD. Lastly, further research would be necessary 
to analyse how these perspectives would relate to actual 
use of medication by patients and prescription habits of 
physicians.
In conclusion, both physicians and patients report a 
large variation in meaningful longevity benefit. Moreover, 
desired benefit differed between patients and physicians 
and exceeded clinically attainable benefit. Clinicians 
should recognise these discrepancies when prescribing 
CVD prevention and implement individualised medicine 
and shared decision-making. In the future, guidance as 
to what realistic benefit entails may be incorporated into 
online decision aids to help physicians and patients reach 
a consensus.
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